Supplements are beneficial in tackling vision loss

Article

Age-related macular degeneration (AMD) is a growing problem throughout the world and is influenced by genetics and behavior.

Carotenoids and retina health

In addition to antioxidant properties, lutein and zeaxanthin are suggested to protect photoreceptors by activating intracellular signaling pathways. These two carotenoids and their metabolites also have been shown to affect cell signaling and modulate the expression of genes, including those involved in detoxification of destructive reactive oxygen species. Lutein and zeaxanthin both have been suggested to regulate apoptosis and angiogenesis, and in addition to their anti-apoptotic effects, lutein and zeaxanthin stimulate the differentiation of photoreceptors, which increases the expression of opsin, the protein that binds to vitamin A retinol.

Adequate vitamin A intake is necessary for optimal vision and particularly important for night vision in older people. Unfortunately, excessive amounts of supplemental beta-carotene interfere with the absorption of lutein and zeaxanthin (one reason that the Age-Related Eye Disease Study 2 has eliminated beta-carotene in one arm of the study).

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.
Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.
Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
© 2025 MJH Life Sciences

All rights reserved.